2023 Women’s Masterclass On Demand
The recordings from the 2023 Women’s Cardiometabolic Health and Wellness Masterclass are now available. Led by co-chairs Pam R. Taub, MD and Erin D.
Category
  • CMHC
Format
  • Conference / meeting
  • Video
Credits
  • 12.00 ACPE Pharmacy
  • 12.00 AMA PRA Category 1 Credit
  • 12.00 ANCC
  • 12.00 Participation
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes
This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, a
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 AAFP
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Category
  • CMHC
  • TME
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit
  • 0.75 ANCC
  • 0.75 Participation
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
According to the Patient: Alopecia Areata in Adolescence
The management of AA in adolescents presents various challenges to dermatology professionals, including identification of AA, limited effective treatment options, and high disease burden.
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Psoriasis in Skin of Color Unplugged: Addressing the Barriers to Patient Care and Relief
Various gaps in the management of psoriasis patients with skin of color (SOC) persist due to a lack of training on SOC and inherent barriers to care. As a result, psoriasis patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden.
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
Traditional treatments for seborrheic dermatitis, including oral and topical steroids, present a variety of challenges including lack of efficacy, adverse events with long-term use, limitations for adherence, and the inability to treat both hair- and non-hair-bearing areas.
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 0.75 AMA PRA Category 1 Credit
  • 0.75 ANCC
  • 0.75 Participation
Clinical Insights into Psoriasis in Patients of Color: Bringing New Data to Light
Various gaps in the management of psoriasis in patients with SOC persist due to a lack of training for dermatology practitioners. As a result, patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden.
Category
  • LivDerm
Format
  • Video
Credits
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches
Topical therapies are considered the mainstay treatment for atopic dermatitis (AD). However, traditional topicals such as corticosteroids and calcineurin inhibitors are associated with limitations for use and safety concerns.
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enha
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation

Pages